A year later, Goswami and Keizer left UCSF and recruited Ranvir Mangat, a drug development expert, to join them in founding InsightRX. The company’s vision was grand but clear: to help healthcare practitioners treat each patient individually by personalizing dosing regimens for complex medications, maximizing treatment efficacy and minimizing drug-related toxicity. “Our platform leverages artificial intelligence (AI) and quantitative pharmacology to help clinicians improve patient care,” says Goswami, CEO of InsightRX.
The company’s core product, InsightRX Nova, seamlessly integrates with hospitals’ electronic health records (EHR), enabling physicians and pharmacists to determine an individualized dosing regimen for a particular drug. For their customers, the InsightRX Nova platform is a goto tool in their armamentarium. “All of the information that is needed to individualize dosing by simulating the patient’s pharmacological and clinical response is pulled out of the EHR in seconds,” explains Goswami.“With a single click, a provider has access to all the relevant information they need to evaluate and individualize therapeutic regimens.”
We envision InsightRX being the leader in leveraging artificial intelligence to develop digital therapeutics which augment medicine at the point of care
Today, InsightRX has amassed a large customer base in the U.S. and Europe and plans to expand across the globe. The company also has partnerships with biotechnology and pharma companies to improve treatment administration of complex drugs. Their portfolio of solutions are currently being utilized in clinical studies funded by the National Institute of Health (NIH). “We are also developing digital therapeutics to augment medicine at the point-of-care and envision being a leader in leveraging AI to improve clinical outcomes across several therapeutic areas. We want to accelerate and support the healthcare industry’s adoption of evidencebased care,” concludes Goswami.
SAN FRANCISCO and LOS ANGELES - InsightRX and CHLA, two leaders in precision dosing, are now working together to bring best-in-class dosing to clinicians. InsightRX will incorporate CHLA's technology, BestDose – and its non-parametric algorithms and models – into the InsightRX Nova precision dosing platform. Many of these models have been evaluated rigorously and published in peer-reviewed medical literature.
"This is really a perfect marriage," says Michael Neely, MD, co-inventor of BestDose, who is Chief of the Division of Infectious Disease at CHLA, and an Associate Professor of Pediatrics at the Keck School of Medicine of USC. He continues: "InsightRX's global customer base, polished user interface, and specialization in EHR integration are a great fit to incorporate BestDose's validated algorithms. After carefully considering other companies in this space, I was impressed by the scientific and technical skills of InsightRX's team to provide state-of-the-art precision dosing products integrated within electronic health record systems."
InsightRX is excited to be able to offer its current and future customers new estimation methods in its InsightRX Nova Platform. "We have always been model- and estimation method-agnostic; this partnership allows clinicians to utilize the best models and algorithms to deliver individualized care to their patients" explained Sirj Goswami, CEO of InsightRX. "We have been fans of Dr. Neely's work for years and we are honored to be able to work with him and push the boundaries of how precision dosing companion applications can maximize therapeutic effectiveness. Our entire team looks forward to learning from Dr. Neely's deep expertise and to collaborating with him on projects across several therapeutic areas."
With this announcement, InsightRX has begun incorporating BestDose's algorithms into its InsightRX Platform. Current BestDose customers can contact their BestDose representative or email firstname.lastname@example.org for more information.